Non-platinum-based chemotherapy for advanced non-small-cell lung cancer

Tumors of the Chest: Biology, Diagnosis and Management

Volumn , Issue , 2006, Pages 289-303

  Scagliotti, Giorgio V ^a   Selvaggi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58549100302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-31040-1_23     Document Type: Chapter

References (124)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable nonsmall cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:254.
2. Soquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19.
3. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs. supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899.
5. Scaghotti G, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92.
7. Le Chevalier T, Scagliotti GV, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced nonsmall-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69.
8. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210.
9. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2000;21:3016.
10. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703.
11. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309.
12. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;1:2286.
13. Rosell R, Gatzemeier U, Betticher H, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539.
14. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung cancer? Result of a comprehensive review of randomized studies in over 2300 patients. Proc Am Soc Clin Oncol 2004;23:630 (Abstract 7068).
15. Hotta K, Ueoka H, Kiura K, et al. A phase I and pharmacokinetic study of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2004;45:77.
16. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small cell lung cancer: a literature based meta-analysis of randomized trials. Ann Oncol 2004;15:1782.
17. Perng RP, Chen YM, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097.
18. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical-benefit response in advanced non-small cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12:1221.
19. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335.
20. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 2004;292:470.
21. Hertel LW, Kroin JS, Misner JW, et al. Synthesis of 2-deoxy-2', 2'-difluoro-D-ribose and 2-deoxy-2', 2'-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1998;53:2406.
22. Kroep JR, Giaccone G, Voon DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999;17:2190.
23. Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000;83:1069.
24. Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 1995;6:19.
25. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 1996;32 A: 243.
26. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297.
27. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine and monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997;15:744.
28. Murphy WK, Fossella FV, Winn RJ, et al. A phase II study of taxol in patients with untreated advanced non-smallcell lung cancer. J Natl Cancer Inst 1993;85:384.
29. Gatzemeier U, Heckmayer M, Neuhauss R, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 1995;22:24.
30. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995;13:1609.
31. Giaccone G, Splinter TAW, De Bruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998;16:2133.
32. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623.
33. Auerbach M, Chaudhry M, Richards P, et al. Phase II study of gemcitabine and paclitaxel in metastatic nonsmall cell lung cancer. Proc Am Soc Clin Oncol 2000;19:522a (Abstract 2052).
34. Giaccone G, Smith EF, van Meerbeeck JP, et al. A phase I-II study of gemcitabine and paclitaxel in advanced nonsmall-cell lung cancer patients. Ann Oncol 2000;11:109.
35. Douillard J, Lerouge D, Monnier A, et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 2001;84:1179.
36. Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIB and IV non-small cell lung cancer. Lung Cancer 2002;38:73.
37. Chen YM, Perng RP, Lee YC, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002;13:108.
38. Hirsh V, Whittom R, Ofiara L, et al. Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 2003;97:2242.
39. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578.
40. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909.
41. Zoh W, Ricotti L, Dal Susino M, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 1999;81:609.
42. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994;70:384.
43. Fossella FV, De Vore R, Kerr R, et al. Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354.
44. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232.
45. Miller VA, Rigas JR, Francis PA, et al. Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968.
46. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus supportive care in chemotherapynaive patients with metastatic or non-resectable localized non-small-cell lung cancer (NSCLC). Lung Cancer 2000;27:145.
47. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095.
48. Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 2001;48:95.
49. Ganjoo KN, Gordon MS, Sandler AB, et al. A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study. Oncology 2002;62:299.
50. Ventriglia M, Estevez R, Alume H, et al. Docetaxel plus gemcitabine: a new combination in the treatment of patients with advanced non-small-cell lung cancer: a preliminary analysis. Ann Oncol 1998;9(S2):96 (Abstract 365).
51. Georgouhas V, Kouroussis C, Androulakis N, et al. Frontline treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 1999;17:914.
52. Rubio G, Blajman C, Capo A, et al. Docetaxel and gemcitabine in metastatic non-small cell lung cancer: a phase II study. Proc Am Soc Clin Oncol 1999;18:522 (Abstract 2012).
53. Hejna M, Kornek GV, Raderer M, et al. Treatment of patients with advanced non small cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 2000;89:516.
54. Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;33:277.
55. Lizon J, Feliu J, Morales S, et al. A phase II study gemcitabine plus docetaxel as a first line treatment in non-smallcell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:270b (Abstract 2833).
56. Miyazaki M, Takeda T, Ichimaru Y, et al. A phase I/II study of docetaxel and gemcitabine combination chemotherapy for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:265b (Abstract 2812).
57. Amenedo M, Mel JR, Huidobro G, et al. Phase II multicenter clinical trial of gemcitabine and docetaxel in advanced non-small-cell lung cancer (NSCLC): final results. Proc Am Soc Clin Oncol 2001;20:265b (Abstract 2813).
58. Menendez P, Gomez PG, Mendez M, et al. A phase II study of a combination of docetaxel and gemcitabine in a weekly schedule as a first line treatment in stages IIIB/IV non-small-cell lung cancer. GOTY STUDY GROUP. Proc Am Soc Clin Oncol 2001;20:256b (Abstract 2777).
59. Syrigos KN, Dionellis G, Alevyzaki F, et al. Biweekly administration of gemcitabine and docetaxel in patients with advanced non-small-cell lung cancer: a phase II study. Proc Am Soc Clin Oncol 2001;20:260b (Abstract 2791).
60. McKay CE, Hainsworth JD, Burris HA, et al. Weekly docetaxel/gemcitabine in the treatment of elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2001;20:260b (Abstract 2793).
61. Popa IE, Stewart K, Smith FP, et al. A phase II trial of gemcitabine and docetaxel in patients with chemotherapynaive, advanced non-small cell lung carcinoma. Cancer 2002;95:1714.
62. Patel R, Reiser LW, Justice GR, et al. ACORN 9901: a multicenter randomized trial of weekly docetaxel+gemcitabine versus weekly paclitaxel+gemcitabine in patients (pts) with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;21:320a (Abstract 1276).
63. Hirsch V, Whittom R, Desjardins P, et al. Docetaxel and gemcitabine administered on day 1 and 8 for metastatic non-small cell carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 2004;46:113.
64. Neubauer MA, Garfield DH, Kurfler PR, et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 2005;47:121.
65. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicenter trial. Lancet 2001;357:1478.
66. Georgoulias V, Samonis G, Papadakis E, et al. Comparison of docetaxel/gemcitabine to docetaxel/cisplatin as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 2001;34(S4):S47.
67. Kakolyris S, Tsiafaki X, Agelidou A, et al. Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;21:296a (Abstract 1182).
68. Kakolyris SS, Kouroussis C, Koukourakis M, et al. A doseescalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 2002;22:1891.
69. Rigas JR, Carey M, Cole B, et al. Multicenter Web-based phase III study to test the survival equivalence of nonplatinum-based (NPB) vs. platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): the Dartmouth NPB Chemotherapy Trial (D0112). Proc Am Soc Clin Oncol 2004;23:631 (Abstract 7071).
70. Herbst RS, Lynch C, Vasconcelles M, et al. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 2001;48:151.
71. De Luca A, Grassi M, Maiello MR, et al. Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? Anticancer Res 2004;24:2985.
72. Isokangas OP, Knuuttila A, Halme M, et al. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 1999;10:1059-1063.
73. Krajnik G, Mohn-Staudner A, Thaler J, et al. Vinorelbinegemcitabine in advanced non-small cell lung cancer (NSCLC): An AASLC phase II trial. Austrian Association for the Study of Lung Cancer. Ann Oncol 2000;11:993.
74. Chen YM, Perng RP, Yang KY, et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000;117:1583.
75. Lorusso V, Carpagnano F, Frasci G, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 2000;18:405.
76. Lilenbaum RC, Cano R, Schwartz M, et al. Gemcitabine and vinorelbine in advanced non small cell lung carcinoma: a phase II study. Cancer 2000;88:557.
77. Bajetta E, Chiara Stani S, De Candis D, et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small cell lung carcinoma: a phase II trial. Cancer 2000;89:763.
78. Laack E, Mende T, Benk J, et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 2001;37:583.
79. Palmeri S, Leonard! V, Gebbia V, et al. Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 2001;34:115.
80. Hirsh V, Langleben A, Ayoub J, et al. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic non-small cell lung carcinoma: a phase II multicenter trial. Cancer 2001;92:830.
81. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 2002;95:340.
82. Hosoe S, Komuta K, Shibata K, et al. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer 2003;88:342.
83. Katakami N, Sugiura T, Nogami T, et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908, Lung Cancer 2004;43:93.
84. Kashii T, Yamamoto N, Takada Y, et al. A randomized phase II study of carboplatin/gemcitabine (CG) versus vinorelbine/gemcitabine (VG) in patients with advanced non-small cell lung cancer (NSCLC); mature results of West Japan Thoracic Oncology Group (WJTOG) 0104. Proc Am Soc Clin Oncol 2004;23:644 (Abstract 7124).
85. Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M, Lane SR. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2005;16:97.
86. Laack E, Dickgreber N, Miiller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004;22:2348.
87. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial. J Clin Oncol 2003;21:3207.
88. Gridelh C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025.
89. Gridelh C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362.
90. Abratt RP, Szczesna A, Mattson K, et al. Vinorelbine (NVB)-carboplatin (CBDCA) vs. non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts) - final results of the Glob 2 phase III with patient benefit analysis. Proc Am Soc Clin Oncol 2004;23:619 (Abstract 7016).
91. Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C. Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2000;49(S1):S25.
92. Feliu J, Lopez Gomez L, Madronal C, et al. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 year or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 1999;86:1463.
93. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529.
94. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003;3:145.
95. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194.
96. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545.
97. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737.
98. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748.
99. Adjei AA, Klein CE, Kastrissios H, et al. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 2000;18:1116.
100. Adjei AA, Nair S, Reuter N, et al. Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: a randomized, phase II trial of three schedules. Proc Am Soc Clin Oncol 2004;23:630 (Abstract 7070).
101. Bahadori HR, Rocha Lima CMS, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423.
102. Nishio M, Oyanagi F, Karato A, et al. Phase I study of biweekly chemotherapy with gemcitabine (GEM) and irinotecan (CPT-11) in previously treated patients (pts) with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;21:219b (Abstract 2693).
103. Georgouhas V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004;22:2602.
104. Georgouhas V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs. irinotecan for the second-line treatment of patients with advanced NSCLC pretreated with docetaxel and cisplatin: a multicenter, randomized, phase II study. Br J Cancer 2004;91:482.
105. Rocha Lima CM, Rizvi NA, Zhang C, et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 2004;15:410.
106. Breton JL, Westeel V, Jacoulet P, et al. Phase I study of paclitaxel (taxol) plus vinorelbine (navelbine) in patients with untreated stage IIIB and IV non-small-cell lung cancer. Lung Cancer 2001;31:295.
107. Kano Y, Akutsu M, Suzuki K, et al. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat 1999;56:79.
108. Stathopoulos GP, Veslemes M, Georgatou N, et al. Paclitaxel and vinorelbine combination in advanced inoperable adenocarcinoma of the lung. A phase II study. Anticancer Res 2003;23:3479.
109. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004;5:1048.
110. Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT, Kris MG. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:1346.
111. Page RD, Smith FP, Geils GF, et al. Prospective multi-center phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:647 (Abstract 7138).
112. Kouroussis C, Androulakis N, Kakolyris S, et al. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer 1998;83:2083.
113. Walls JA, O'Rourke M, Garfield D, Asmar L. First-line therapy of Taxotere and Navelbine in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:547a (Abstract 2158).
114. Murren JR, Davies M. Irinotecan and taxane combination for non-small cell lung cancer. Clin Lung Cancer 2002;3(S1):S5.
115. Raez LE, Rosado MF, Santos ES, Reis IM. Irinotecan and docetaxel as first-line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer: experience from a prematurely closed phase II study. Lung Cancer 2004;45:131.
116. Ziotopoulos P, Chandrinos V, Samaras N, et al. A phase II study of docetaxel plus irinotecan (DOCIRI) in chemo-naive patients with non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:679 (Abstract 7267).
117. Ramalingam S, Dobbs TW, Coke DE, Wojtowicz-Praga S, Belani CP. Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): results of a multi-center, phase II study. Proc Am Soc Clin Oncol 2004;23:687 (Abstract 7298).
118. Yamamoto N, Fukuoka M, Negoro S, et al. Randomized phase II study of docetaxel/cisplatin versus docetaxel/irinotecan in advanced non-small cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group study (WJTOG9803). Br J Cancer 2004;90:87.
119. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 1997;8:231.
120. Kasai T, Oka M, Soda H, et al. Phase I and pharmacokinetic study of irinotecan and paclitaxel for patients with advanced non-small cell lung cancer. Eur J Cancer 2002;38:1871.
121. Yamamoto N, Negoro S, Chikazawa H, Shimizu T, Fukuoka M. Pharmacokinetic interaction of the combination paclitaxel and irinotecan in vivo and clinical study. Proc Am Soc Clin Oncol 1999;18:187a (Abstract 718).
122. Rosen P, Schaaf LJ, Knuth DW, et al. Phase I and pharmacokinetic trial of CPT-11 and paclitaxel in patients with advanced cancers. Proc Am Soc Clin Oncol 1999;18:177a (Abstract 679).
123. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001;19(4):1071.
124. Monnerat C, Le Chevalier T, Kelly K, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10(16):5439.